Showing posts with label Treatment of. Show all posts
Showing posts with label Treatment of. Show all posts
Tuesday, September 8, 2026

FDA Approves Veppanu (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

›
Arvinas, Inc. (Nasdaq: ARVN), with its partner Pfizer Inc. (NYSE: PFE), announced  the U.S. Food and Drug Administration (FDA)    approval f...
Monday, August 31, 2026

FDA Approves Idvynso (doravirine and islatravir) for the Treatment of HIV-1 Infection in Adults

›
In continuation of my update on   Doravirine Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Foo...
Thursday, July 23, 2026

FDA Approves Nuzolvence (zoliflodacin) for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

›
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA),   announced   the U.S. Food and Drug Administration (FDA)  a...
Tuesday, July 21, 2026

FDA Approves Aqvesme (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

›
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for pati...
Thursday, May 21, 2026

FDA Approves Lasix ONYU (furosemide) for Treatment of Edema in Heart Failure

›
SQ Innovation, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its drug-device combination Lasix ONYU (fu...
Tuesday, November 4, 2025

FDA Approves Onapgo (apomorphine hydrochloride) for the Treatment of Motor Fluctuations in Adults with Advanced Parkinson’s Disease

›
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatm...